Mitochondria

Ascentage Pharma Announces Another Milestone Payment from Its Licensee UNITY Biotechnology, Rapidly Advancing the Clinical Development of Senolytic Drug Candidate UBX1325

Retrieved on:

Thursday, July 29, 2021

Cancer research, Branches of biology, Apoptosis, Bcl-xL, Mitochondria, Senolytic, Targeted therapy, Medicine, Health sciences

UBX1325 is developed from BM-962, a drug candidate licensed to UNITY by Ascentage Pharma for the clinical development targeting age-related diseases.

Key Points:

UBX1325 is developed from BM-962, a drug candidate licensed to UNITY by Ascentage Pharma for the clinical development targeting age-related diseases.
According to the terms of the licensing agreement previously entered into between Ascentage Pharma and UNITY, this progress in clinical development will qualify Ascentage Pharma for a milestone payment in the amount of US$2 million, which will be paid in UNITY common stock.
UBX1325 is a small-molecule inhibitor of Bcl-xL, and the first senolytic therapeutic clinically evaluated in an ophthalmological setting.
"The continued progress in the clinical development of UBX1325 demonstrated Ascentage Pharma's capabilities in the research and development of apoptosis-targeted therapies," said Dr. Dajun Yang, Chairman & CEO of Ascentage Pharma.

BERG To Present Latest Glioblastoma [GBM] Treatment Data At Society For Neuro-Onocology 2021 Meeting

Retrieved on:

Wednesday, July 14, 2021

Cellular respiration, Branches of biology, Mitochondria, Biology, Natural sciences, Biochemistry, Carbohydrates, Glycolysis, Mitochondrion

"Brain cancers, such as GBM, are destroying patients and their families," said Dr.Niven R. Narain, CEO, President and Co-founder of BERG.

Key Points:

"Brain cancers, such as GBM, are destroying patients and their families," said Dr.Niven R. Narain, CEO, President and Co-founder of BERG.
BPM 31510 is a unique therapeutic modality, that specifically targets cell metabolism and shifts the cancer's glycolytic dependency toward mitochondrial oxidative phosphorylation.
BERG LLC is a clinical-stage, artificial intelligence-powered biotech leveraging its proprietary platform, Interrogative Biology, to map disease and revolutionize treatments across oncology, neurology and rare diseases.
We are grateful to our patient and family partners for their participation in these critical efforts to improve cancer care.

Reneo Pharmaceuticals Announces Partial Waiver of Lock-Up Restriction

Retrieved on:

Friday, July 9, 2021

Branches of biology, Biology, Cellular respiration, Mitochondrial genetics, Cell biology, Fatty acids, Mitochondria, Mitochondrion, Mitochondrial disease, Beta oxidation, Acyl-CoA, ATP-sensitive potassium channel

The waiver for Ms. Johnson will take effect on July 13, 2021 and the shares may be sold on or after such date.

Key Points:

The waiver for Ms. Johnson will take effect on July 13, 2021 and the shares may be sold on or after such date.
Reneo is a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP).
Reneo is developing REN001 to modulate genes critical to metabolism and generation of ATP, which is the primary source of energy for cellular processes.
REN001 has been shown to increase transcription of genes involved in mitochondrial function and increase fatty acid oxidation, and may increase production of new mitochondria.

Reneo Pharmaceuticals to Present at the Ladenburg Thalmann 2021 Healthcare Conference

Retrieved on:

Wednesday, July 7, 2021

Branches of biology, Mitochondrial genetics, Mitochondrial diseases, Cellular respiration, Mitochondria, Mitochondrion, Mitochondrial disease, Aerie Pharmaceuticals, Neuropathy, ataxia, and retinitis pigmentosa

SAN DIEGO, July 07, 2021 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare, genetic, mitochondrial diseases, today announced that it will provide a corporate update and participate in one-on-one investor meetings at the Ladenburg Thalmann 2021 Healthcare Conference, to be held virtually on July 13-14, 2021.

Key Points:

SAN DIEGO, July 07, 2021 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare, genetic, mitochondrial diseases, today announced that it will provide a corporate update and participate in one-on-one investor meetings at the Ladenburg Thalmann 2021 Healthcare Conference, to be held virtually on July 13-14, 2021.
Reneo is a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP).
Reneo is developing REN001 to modulate genes critical to metabolism and generation of ATP, which is the primary source of energy for cellular processes.
REN001 has been shown to increase transcription of genes involved in mitochondrial function and increase fatty acid oxidation, and may increase production of new mitochondria.

Precision BioSciences Announces New Study Published in Nature Communications Using Engineered ARCUS Nuclease to Target Mutant Mitochondrial DNA In Vivo

Retrieved on:

Tuesday, June 1, 2021

Additionally, both mutant and wild-type mtDNA can co-exist within the mitochondria of a cell, a phenomenon called mtDNA heteroplasmy.

Key Points:

Additionally, both mutant and wild-type mtDNA can co-exist within the mitochondria of a cell, a phenomenon called mtDNA heteroplasmy.
When specific threshold levels of mutant mtDNA are reached, cell function can be compromised, and disease can manifest1.
In this study, a mitochondrial-targeted ARCUS nuclease (mitoARCUS) used to edit mutant mtDNA was particularly effective, in part because of the nucleases small size and single protein nature.
Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its wholly proprietary ARCUS genome editing platform.

Oncocyte Reports First Quarter 2021 Financial Results and Provides Corporate Update

Retrieved on:

Monday, May 17, 2021

Medicine, Branches of biology, Mitochondria, Oncocyte, Oncology, Immunotherapy, BlackBerry PlayBook, Health sciences

We also gain access to broader intellectual property that may enable Oncocyte to offer additional innovative blood-based tests.

Key Points:

We also gain access to broader intellectual property that may enable Oncocyte to offer additional innovative blood-based tests.
From an execution standpoint, we will replicate our proven DetermaIO playbook as we rapidly launch DetermaCNI\xe2\x84\xa2 for blood-based immunotherapy response monitoring for research use in pharmaceutical clinical trials in late 2021.
Since inception, Oncocyte generated revenues for the first time in the first quarter of 2020, therefore comparison of current quarter consolidated revenues to the first quarter of 2020 is not meaningful.
Oncocyte undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.\n'

Stealth BioTherapeutics to Report First Quarter Financial Results on Tuesday, May 18, 2021

Retrieved on:

Tuesday, May 11, 2021

Branches of biology, Molecular biology, Cellular respiration, Mitochondria, Mitochondrion, Mitochondrial disease, Mito, Biology

b"BOSTON, May 11, 2021 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announcedthat it will report first quarter 2021 financial results on Tuesday, May 18, 2021, before the market opens.\nManagement will host a conference call at8:30 am ETthat day to discuss the financial results and provide a general business update.

Key Points:

b"BOSTON, May 11, 2021 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announcedthat it will report first quarter 2021 financial results on Tuesday, May 18, 2021, before the market opens.\nManagement will host a conference call at8:30 am ETthat day to discuss the financial results and provide a general business update.
The call can be accessed by dialing (877)-407-0989 (domestic) or (201)-389-0921 (international) and referencing conference ID 13719019.
A live audio webcast of the event can be accessed by visiting the Investors & News section of Stealth's Investor website, https://investor.stealthbt.com/ .
Mitochondria, found in nearly every cell in the body, are the body's main source of energy production and are critical for normal organ function.

CohBar to Announce 2021 First Quarter Financial Results and Provide Business Update on May 17, 2021

Retrieved on:

Monday, May 3, 2021

Branches of biology, Cellular respiration, Mitochondria, Mitochondrion, Peptide, XC2, Mitochondrial disease, Biology

To access the recording please dial (844) 512-2921 in the U.S. and Canada, or (412) 317-6671 internationally, and reference Conference ID# 13718702.

Key Points:

To access the recording please dial (844) 512-2921 in the U.S. and Canada, or (412) 317-6671 internationally, and reference Conference ID# 13718702.
To date, the company has discovered more than 100 mitochondrial derived peptides and generated over 1,000 analogs.
CohBar\xe2\x80\x99s efforts focus on the development of these peptides into therapeutics that offer the potential to address a broad range of diseases\xc2\xa0associated with the underlying impact of mitochondrial dysfunction.
The company\xe2\x80\x99s lead compound, CB4211, is in the Phase 1b stage of a Phase 1a/1b clinical trial for NASH and obesity.

Oncocyte to Present New Data on DetermaIO™ Test as a Predictor of Immunotherapy Response in Renal Cell Cancer at the 2021 ASCO Annual Meeting

Retrieved on:

Wednesday, April 28, 2021

Clinical medicine, Medicine, Cancer, Cancer treatments, Mitochondria, Oncocyte, Oncology, Adjuvant therapy, Renal cell carcinoma, Treatment of cancer

The presentation will feature data from a study of Oncocyte\xe2\x80\x99s novel predictor of immunotherapy response, DetermaIO\xe2\x84\xa2, demonstrating test performance in renal cell cancer.\n\xe2\x80\x9cWe look forward to presenting these new data which demonstrate DetermaIO, our gene expression-based test which identifies likely immunotherapy responders versus non-responders, is validated in renal cell carcinoma,\xe2\x80\x9d said Doug Ross, M.D., Ph.D., Chief Science Officer of Oncocyte.

Key Points:

The presentation will feature data from a study of Oncocyte\xe2\x80\x99s novel predictor of immunotherapy response, DetermaIO\xe2\x84\xa2, demonstrating test performance in renal cell cancer.\n\xe2\x80\x9cWe look forward to presenting these new data which demonstrate DetermaIO, our gene expression-based test which identifies likely immunotherapy responders versus non-responders, is validated in renal cell carcinoma,\xe2\x80\x9d said Doug Ross, M.D., Ph.D., Chief Science Officer of Oncocyte.
The Company, through its proprietary tests and pharmaceutical services business, aims to help save lives and improve outcomes by accelerating and optimizing the diagnosis and treatment of cancer.
The Company\xe2\x80\x99s tests and services present multiple opportunities to advance cancer care while also driving revenue growth for the Company.
Oncocyte launched DetermaRx\xe2\x84\xa2, a test that identifies early-stage lung cancer patients who are at high risk for cancer recurrence post-resection and predicts benefit from adjuvant chemotherapy.

LUCA Science Announces the Opening of a New Subsidiary in the UK and Expansion on the Collaboration With the University of Oxford on the Development of Novel Mitochondrial Therapeutics

Retrieved on:

Wednesday, April 7, 2021

LUCA Science UK will focus on research collaborations with the University of Oxford using LUCA Sciences proprietary Mitochondria therapy in advancing treatment of intra-uterine growth restriction (IUGR) for mothers and babies.

Key Points:

LUCA Science UK will focus on research collaborations with the University of Oxford using LUCA Sciences proprietary Mitochondria therapy in advancing treatment of intra-uterine growth restriction (IUGR) for mothers and babies.
LUCA Science UK will be based in Oxford.
LUCA Science is a pioneer in developing a new class of mitochondrial therapy to restore cellular bioenergetics in dysfunctional tissues.
LUCA Science has developed a novel method to isolate proprietary functional mitochondria which can then be stored and delivered as a biopharmaceutical agent.